Clinical Trial

Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood

Study acronym: RISP-OTOTOX

Not Yet Recruiting

Record status

This record was last updated May 4, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Summary

This study is aimed at people treated for cancer before the age of 25, who have been followed for at least 5 years, and who are now aged between 18 and 50. It is a prospective, multicenter, non-randomized study. The main aim of the project is to identify hearing impaired patients using the iAudiogram medical device, and to analyze the risk factors associated with the risk of hearing impairment. Around 500 patients will take part in this study in France. Participation in this research project will consist in carrying out a hearing test (audiogram with tonal audiometry) with the iAudigram medical device (at Gustave Roussy, Curie or Necker Hospital) and completing self-questionnaires focusing on ototoxicity and its consequences.

Trial Details

NCT Number	NCT06957132
Lead Sponsor	Gustave Roussy, Cancer Campus, Grand Paris
Conditions	Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced, Pediatric Cancer
Enrollment	500 participants
Start Date	2025-05
Primary Completion	2026-04 (estimated)
Study Completion	2026-04 (estimated)
Updated on ClinicalTrials.gov	2025-05-04